Good for them, though wouldn't it make a lot of sense to share this with Pfizer if that's the case and if that's possible to transfer the method, for some amount of compensation? It's a huge cost difference anyway, so why not pay Moderna the difference and get improved logistics?
-
This Tweet is unavailable.
-
-
Perhaps because it would then be a different vaccine and need the whole approval business all over again?
1 reply 0 retweets 3 likes -
Pfizer/BioNTech actually does have other candidates in the pipeline that may be improved.
1 reply 0 retweets 1 like
Yeah, the implications aren't just a little bit more cost for Pfizer.
2:45 PM - 16 Dec 2020
0 replies
0 retweets
0 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.